Viveve Medical, Inc. (VIVE)
OTCMKTS: VIVE · Delayed Price · USD
0.0003
0.00 (0.00%)
Apr 19, 2024, 11:51 AM EDT - Market closed
Company Description
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence.
The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components.
It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally.
Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Viveve Medical, Inc.
| Country | Colombia |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Ms. Deborah Ann Jorn M.B.A. |
Contact Details
Address: 345 Inverness Drive South, Building B, Suite 250 Englewood, Colorado 80112 United States | |
| Phone | 4085301900 |
| Website | viveve.com |
Stock Details
| Ticker Symbol | VIVE |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000879682 |
| CUSIP Number | 92852W303 |
| ISIN Number | US92852W5013 |
| Employer ID | 04-3153858 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Jim B. Robbins | Senior Vice President of Finance and Administration and Principal Accounting & Financial Officer |
| Deborah Ann Jorn M.B.A. | Senior Advisor to the Chief Executive Officer and Director |
| Martin Kerber P.E. | Vice President of Research, Development and Operations |
| Jeannie Swindle | Senior Director of Corporate Communications |
| Jeff Sinclair | Vice President of International Sales |
| Gary Kaiser | Vice President of Global Marketing |
| Lori McMillan | Vice President of Human Resources |
| Suzon D. Lommel | Senior Vice President of Regulatory and Quality Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 6, 2023 | 15-12G | Securities registration termination |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 30, 2023 | EFFECT | Notice of Effectiveness |
| Jan 27, 2023 | RW | Filing |
| Jan 27, 2023 | POS AM | Post-Effective amendments for registration statement |